Comorbidity, age and overall survival in cetuximabtreated patients with advanced colorectal cancer (ACRC)-results from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care

Annals of Oncology

Volumn 22, Issue 1, 2011, Pages 118-126

  Asmis, T R ^a   Powell, E ^a   Karapetis, C S ^b   Jonker, D J ^a   Tu, D ^c   Jeffery, M ^d   Pavlakis, N ^e   Gibbs, P ^f   Zhu, L ^c   Dueck, D A ^g   Whittom, R ^h   Langer, C ⁱ   O'Callaghan, C J ^c  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c Queen's Cancer Research Institute   (Canada)

^d CHRISTCHURCH HOSPITAL   (New Zealand)

^e ROYAL NORTH SHORE HOSPITAL   (Australia)

^f ROYAL MELBOURNE HOSPITAL   (Australia)

^g THUNDER BAY REGIONAL HEALTH SCIENCES CENTRE   (Canada)

^h HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

ⁱ BRISTOL MYERS SQUIBB   (United States)

Author keywords

Advanced colorectal cancer; Age; Cetuximab; Charlson comorbidity score; Comorbidity

Indexed keywords

ALKALINE PHOSPHATASE; CETUXIMAB; FLUOROPYRIMIDINE; IRINOTECAN; K RAS PROTEIN; LACTATE DEHYDROGENASE; OXALIPLATIN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGE; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMORBIDITY; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PATIENT CARE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; VOMITING;

EID: 78650396059     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq309     Document Type: Article

References (46)

1. Committee S, Society CC. Canadian Cancer Statistics 2009. Toronto: Canadian Cancer Society 2009.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
3. National Cancer Institute. Surveillance, epidemiology and end results. http://seer.cancer.gov/statfacts/(3 June 2010, date last accessed).
4. Smith B, Smith G, Hurria A et al. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 2009; 27: 2758-2765.
5. Hutchins LF, Unger JM, Crowley JJ et al. Underrepresentation of patients 65 years of age or older in cancer treatment trials. N Engl J Med 1999; 341: 2061-2067.
6. Balducci L. Geriatric oncology challenges for the new century. Eur J Cancer 2000; 36: 1741-1754.
7. Kumar A, Soares H, Balducci L et al. Treatment tolerance and efficacy in geriatric oncology: a systematic review of Phase III randomized trials conducted by five National Cancer Institute-sponsored Cooperative Groups. J Clin Oncol 2007; 25: 1272-1276.
8. Sanoff H, Bleiberg H, Goldberg R. Managing older patients with colorectal cancer. J Clin Oncol 2007; 25: 1891-1897.
9. Lichtman S, Wildiers H, Chatelut E et al. International Society of Geriatric Oncology Chemotherapy Taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol 2007; 25: 1832-1843.
10. Jonker DJ, Maroun J, Kocha W. Survival benefit of chemotherapy in metastatic colorectal cancer: a meta-analysis of randomized controlled trials. Br J Cancer 2000; 82: 1789-1794.
11. Goldberg R, Sargent D, Morton R et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
12. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
13. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
14. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-4091.
15. Young KW, Maeda K, Noda E et al. Efficacy of m-FOLFOX6 therapy for colorectal cancer in elderly patients. Gan To Kagaku Ryoho 2007; 34: 1833-1836.
16. D'Andre S, Sargent D, Cha S et al. 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a North Central Cancer Treatment Group study. Clin Colorectal Cancer 2005; 4: 325-331.
17. Sastre J, Marcuello E, Masutti B et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. J Clin Oncol 2005; 23: 3545-3551.
18. Kabbinavar F, Hurwitz H, Yi J et al. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009; 27: 199-205.
19. Begg C, Carbone P. Clinical trials and drug toxicity in the elderly: the experience of the Eastern Cooperative Oncology Group. Cancer 1983; 52: 1986-1992.
20. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer 2000; 36: 453-471.
21. Klabunde CN, Legler JM, Warren JL et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal and lung cancer patients. Ann Epidemiol 2007; 17: 584-590.
22. Gosney MA. Clinical assessment of elderly people with cancer. Lancet Oncol 2005; 6: 790-797.
23. Charlson ME, Pompei P, Ales KL et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-383.
24. Hall WH, Ramachandran R, Narayan S et al. An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 2004; 4: 94.
25. Rieker R, Hammer E, Eisele R et al. The impact of comorbidity on the overall survival and the cause of death in patients after colorectal cancer resection. Langenbecks Arch Surg 2002; 387: 72-76.
26. Jonker D, O'Callaghan C, Karapetis C et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357: 2040-2048.
27. Au H, Karapetis C, O'Callaghan C et al. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. J Clin Oncol 2009; 27: 1822-1828.
28. Karapetis C, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765.
29. Asmis T, Ding K, Seymour L et al. Age and comorbidity as independent prognostic factors in the treatment of non-small cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group Trials. J Clin Oncol 2008; 26: 54-59.
30. Gripp S, Moeller S, Bolke E et al. Survival prediction in terminally ill cancer patients by clinical estimates, laboratory tests, and self-rated anxiety and depression. J Clin Oncol 2007; 25: 3313-3320.
31. Evans C, McCarthy M. Prognostic uncertainty in terminal care: can the Karnofsky index help? Lancet 1985; 1: 1204-1206.
32. Mor V, Laliberte L, Morris J et al. The Karnofsky performance status scale. An examination of its reliability and validity in a research setting. Cancer 1984; 53: 2002-2007.
33. Maione P, Perrone F, Gallo C et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small cell lung cancer receiving chemotherapy: a prognostic analysis of the Multicenter Italian Lung Cancer in the Elderly Study. J Clin Oncol 2005; 23: 6865-6872.
34. Janssen-Heijnen M, Schipper R, Razenberg P et al. Prevalence of comorbidity in lung cancer patients and its relationship with treatment: a population-based study. Lung Cancer 1998; 21: 105-113.
35. DeMarco M, Janssen-Heijnen M, van der Heijden L et al. Comorbidity and colorectal cancer according to subsite and stage: a population-based study. Eur J Cancer 2000; 36: 95-99.
36. Extermann M, Overcash J, Lyman G et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998; 16: 1582-1587.
37. Wedding U, Rohrig B, Klippstein A et al. Co-morbidity and functional deficits independently contribute to quality of life before chemotherapy in elderly cancer patients. Support Care Cancer 2007; 15: 1097-1104.
38. Hall S. A user's guide to selecting a comorbidity index for clinical research. J Clin Epidemiol 2006; 59: 849-855.
39. Neugut A, Fleischauer A, Sundararajan V et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol 2002; 20: 2643-2650.
40. Sundararajan V, Mitra N, Jacobson J et al. Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer. Ann Intern Med 2002; 136: 349-357.
41. Yancik R. Cancer burden in the aged; an epidemiologic and demographic overview. Cancer 1997; 80: 1273-1283.
42. Sargent D, Goldberg R, Jacobson S et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-1097.
43. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III randomized trial. J Natl Cancer Inst 2003; 95: 362-372.
44. Heit J, Silverstein M, Mohr D et al. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-815.
45. Khorana A, Francis C, Culakova E et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007; 5: 632-634.
46. Asmis T, Templeton M, Trocola R et al. Incidence and significance of thromboembolic events (TE) in patients with gastrointestinal (GI) and non-GI malignancies on systemic cytotoxic therapy. Journal of Clinical Oncology 2007; 25: (Abstr 9049).